Lupin plans to launch 3-4 generic drugs in U.S. by end-March
MUMBAI (Reuters) - Lupin Ltd(LUPN.NS), India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.
The Mumbai-based drugmaker has so far launched six products in this fiscal year in the United States, which generates about 42 percent of its total formulation sales.
The drugmaker earlier reported a forecast-beating 42.6 percent rise in quarterly net profit to 3.35 billion rupees.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Hong Kong protests approach potential National Day flashpoint
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- Obama, Modi discuss trade, climate, Islamic State at White House
- UPDATE 3-Drug, medical device companies paid billions to U.S. physicians, hospitals in 2013 -data
- UPDATE 2-U.S. charges four with stealing $100 mln in software, data
U.S. President Barack Obama and Indian Prime Minister Narendra Modi worked to deepen improving ties between their countries on Tuesday, but emerged from their second meeting in two days with little in the way of major agreements. Story | Full Coverage
China final HSBC PMI steady in September on stronger global demand but risks remain Full Article